uPAR-PET/MRI in Glioblastoma Multiforme
uPAR-PET/MRI in Glioblastoma Multiforme
The purpose of this study is to investigate the applicability of urokinase plasminogen
 activator receptor (uPAR) Positron Emission Tomography (PET) / MRI molecular imaging of
 glioblastoma.
68Ga-NOTA-AE105 is a radioligand targeting urokinase plasminogen activator receptor (uPAR),
 which is a promising imaging biomarker of tumor aggressiveness. 68Ga-NOTA-AE105 PET/MRI will
 be applied in patients suspected of glioblastoma multiforme. The uptake of the radioligand
 68Ga-NOTA-AE105 will be compared and correlated with expression of the molecular target: uPAR
 using immunohistochemistry of tumor tissue samples obtained during routine stereotactic
 biopsies or operation. In addition, the semiquantitative uptake (standard uptake values,
 SUVs) of 68Ga-NOTA-AE105 in tumor tissue will be correlated with overall survival and
 progression free survival
Inclusion Criteria:

 -  Patients where imaging with MRI or CT is suspicious of having glioblastoma multiforme,
 and patients, and who is referred for stereotactic biopsy, chemotherapy or surgery

 -  The participants must be capable of understanding and giving full informed written
 consent

 -  age above 18 years

 Exclusion Criteria:

 -  Pregnancy

 -  Lactation/breast feeding

 -  Age above 85 years old

 -  Weight above 140 kg

 -  Known allergy towards 68Ga-NOTA-AE105